Summary & Overview
HCPCS Level II L8603: Collagen Urethral Bulking Agent, 2.5 ml Syringe
HCPCS Level II code L8603 represents an injectable collagen bulking agent packaged as a 2.5 ml syringe and includes shipping and necessary supplies. The code is used to bill for the device itself when administered to achieve tissue bulking in the urinary tract, commonly for management of urinary incontinence. Nationally, device and supply codes like L8603 matter because they capture costs for durable medical supplies and implants that affect outpatient procedural spending and coverage determinations.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for urethral bulking, the role of this collagen implant in outpatient care, and what to expect from payer coverage patterns. The publication outlines benchmarks for utilization and pricing where available, notes relevant policy and coverage considerations affecting device reimbursement, and highlights coding nuances tied to supply-inclusive device codes.
This summary is intended to help clinicians, billing staff, and policy analysts quickly understand what L8603 denotes, the typical care setting for its use, and the payer landscape that shapes access and payment for collagen-based urethral bulking agents.
Billing Code Overview
HCPCS Level II code L8603 describes an injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, and includes shipping and necessary supplies. This product is used as a collagen-based urethral bulking agent intended to treat urinary incontinence or other urinary tract conditions where tissue bulking is clinically indicated.
Service Type: Injectable implant administration / implantable medical supply
Typical Site of Service: Outpatient clinic or physician office, and may also be provided in ambulatory surgical centers depending on clinical workflow and practitioner preference.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with symptomatic stress urinary incontinence or urinary sphincter deficiency who has failed conservative measures (pelvic floor therapy, pessary use, or behavioral modification) and is referred to a urologist or urogynecologist for endoscopic periurethral injection of a bulking agent. The procedure is performed in an ambulatory surgery center or office-based procedure room under local anesthesia with or without mild sedation. After pre-procedure counseling and informed consent, the patient is placed in lithotomy position, the urethra is anesthetized, and cystoscopic guidance is used to inject the collagen bulking agent (L8603) into the submucosal tissue at the bladder neck or proximal urethra to improve coaptation and reduce urinary leakage. Post-procedure monitoring includes brief observation for urinary retention, hematuria, or urinary tract infection, with instructions for hydration, activity restrictions, and signs of complications. Billing typically includes the injectable bulking agent supply (L8603) and may be accompanied by CPT codes for cystoscopy, anesthesia, or facility services depending on site of service and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | Use when the bulking injection is a separate, identifiable procedure from another service on the same date (for example distinct cystoscopic intervention). |